MA51678A - Méthodes de traitement de l'amyotrophie musculaire - Google Patents

Méthodes de traitement de l'amyotrophie musculaire

Info

Publication number
MA51678A
MA51678A MA051678A MA51678A MA51678A MA 51678 A MA51678 A MA 51678A MA 051678 A MA051678 A MA 051678A MA 51678 A MA51678 A MA 51678A MA 51678 A MA51678 A MA 51678A
Authority
MA
Morocco
Prior art keywords
amyotrophy
muscle
treatment methods
treatment
methods
Prior art date
Application number
MA051678A
Other languages
English (en)
Inventor
Wildon Farwell
Alexander Mccampbell
John Staropoli
Christopher Cody Stebbins
Guolin Zhao
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA51678A publication Critical patent/MA51678A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
MA051678A 2018-01-25 2019-01-25 Méthodes de traitement de l'amyotrophie musculaire MA51678A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622027P 2018-01-25 2018-01-25
US201862684507P 2018-06-13 2018-06-13
US201862738134P 2018-09-28 2018-09-28

Publications (1)

Publication Number Publication Date
MA51678A true MA51678A (fr) 2020-12-02

Family

ID=65529774

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051678A MA51678A (fr) 2018-01-25 2019-01-25 Méthodes de traitement de l'amyotrophie musculaire

Country Status (13)

Country Link
US (2) US11474113B2 (fr)
EP (1) EP3743728A1 (fr)
JP (2) JP7506606B2 (fr)
KR (1) KR102742415B1 (fr)
CN (2) CN119679944A (fr)
AU (1) AU2019211446B2 (fr)
BR (1) BR112020015082A2 (fr)
CL (1) CL2020001936A1 (fr)
IL (1) IL276180B2 (fr)
MA (1) MA51678A (fr)
MX (1) MX2020007852A (fr)
SG (1) SG11202006677XA (fr)
WO (1) WO2019147960A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7506606B2 (ja) 2018-01-25 2024-06-26 バイオジェン・エムエイ・インコーポレイテッド 脊髄性筋萎縮症を治療する方法
MA54383A (fr) 2018-12-06 2021-10-13 Biogen Ma Inc Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique
EP3924739A1 (fr) 2019-02-12 2021-12-22 Biogen MA Inc. Biomarqueurs de la leucoencéphalopathie multifocale progressive
KR102858957B1 (ko) 2019-06-11 2025-09-12 쿨리케 & 소파 네덜란드 비.브이. 광학 시스템 특성의 조정에 의해 개별 콤포넌트의 어셈블레에서의 위치 오차 보상
RS64879B1 (sr) 2019-07-19 2023-12-29 Biogen Ma Inc Postupci za lečenje ili prevenciju spinalne mišićne atrofije
JP2024526060A (ja) * 2021-06-08 2024-07-17 アレクトル エルエルシー 抗ソルチリン抗体の使用方法
WO2023240236A1 (fr) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement de troubles liés à l'amyotrophie spinale
IL326390A (en) 2023-08-10 2026-04-01 Univ Pennsylvania Compositions and methods for treatment of spinal muscular atrophy
WO2025115644A1 (fr) * 2023-11-27 2025-06-05 公立大学法人横浜市立大学 Méthode de prédiction de pronostic et d'effet thérapeutique sur une maladie des motoneurones

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4582789A (en) 1984-03-21 1986-04-15 Cetus Corporation Process for labeling nucleic acids using psoralen derivatives
US4563417A (en) 1984-08-31 1986-01-07 Miles Laboratories, Inc. Nucleic acid hybridization assay employing antibodies to intercalation complexes
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
DE69132905T2 (de) 1990-12-06 2002-08-01 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Detektion von Nukleinsäuresequenzen
US6027880A (en) 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
WO1997046313A1 (fr) 1996-06-07 1997-12-11 Eos Biotechnology, Inc. Nouveaux reseaux d'oligonucleotides lineaires immobilises
CA2439402A1 (fr) 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Procede de reaction en chaine de la polymerase
EP1379545A2 (fr) 2001-04-19 2004-01-14 Gesellschaft für biotechnologische Forschung mbH (GBF) Procede de production de series d'anticorps stables regenerables
US6812341B1 (en) 2001-05-11 2004-11-02 Ambion, Inc. High efficiency mRNA isolation methods and compositions
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
US7252976B2 (en) 2002-08-28 2007-08-07 Board Of Regents The University Of Texas System Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
PT2548560E (pt) 2005-06-23 2015-09-22 Isis Pharmaceuticals Inc Composições e métodos de modulação da excisão-união de smn2
CA2659376C (fr) * 2006-08-01 2014-10-14 Jasbir Singh 2,4-diaminoquinazolines contre l'amyotrophie spinale
WO2008127974A1 (fr) * 2007-04-13 2008-10-23 The Trustees Of Columbia University In The City Of New York Système de culture à base de cellules souches pour la mise au point de médicaments
SI3988660T1 (sl) 2009-05-02 2025-09-30 Genzyme Corporation Genska terapija za nevrodegenerativne motnje
KR20220084437A (ko) 2009-06-17 2022-06-21 바이오젠 엠에이 인코포레이티드 대상에게서 smn2 스플라이싱을 조정하기 위한 조성물 및 방법
US8465727B2 (en) 2009-10-06 2013-06-18 University of Pittsburgh—of the Commonwealth System of Higher Education Biomarkers for the diagnosis of ALS
EP2943225A4 (fr) 2013-01-09 2016-07-13 Ionis Pharmaceuticals Inc Compositions et procédés pour la modulation de l'épissage de smn2 chez un sujet
HUE050704T2 (hu) 2014-04-01 2020-12-28 Biogen Ma Inc Összetételek a SOD-1 expressziójának modulálására
US10024870B2 (en) * 2014-04-02 2018-07-17 Wisconsin Alumni Research Foundation Therapeutic and diagnostic methods and compositions for neurodegenerative diseases
US20170044538A1 (en) 2014-04-17 2017-02-16 Biogen Ma Inc. Compositions and Methods for Modulation of SMN2 Splicing in a Subject
WO2016040748A1 (fr) 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions et procédés de détection d'une protéine smn chez un patient et traitement d'un patient
JP2019509272A (ja) * 2016-02-23 2019-04-04 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation 脊髄性筋萎縮症の治療のための併用療法
EP3463376A1 (fr) * 2016-06-03 2019-04-10 F. Hoffmann-La Roche AG Nouveau traitement de la sma
WO2018218219A1 (fr) * 2017-05-26 2018-11-29 University Of Miami Détermination de l'apparition de la sclérose latérale amyotrophique
TW202413649A (zh) * 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
JP7506606B2 (ja) 2018-01-25 2024-06-26 バイオジェン・エムエイ・インコーポレイテッド 脊髄性筋萎縮症を治療する方法
EA201992364A1 (ru) * 2018-04-02 2020-03-23 Кохерус Байосайенсис Инк. АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА
WO2020061355A2 (fr) 2018-09-20 2020-03-26 Biogen Ma Inc. Protéine neurofilamenteuse sérique pour guider une intervention thérapeutique dans la sclérose en plaques
MA54383A (fr) 2018-12-06 2021-10-13 Biogen Ma Inc Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique
TWI906204B (zh) 2018-12-14 2025-12-01 美商百健Ma公司 用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法
EP3924739A1 (fr) 2019-02-12 2021-12-22 Biogen MA Inc. Biomarqueurs de la leucoencéphalopathie multifocale progressive

Also Published As

Publication number Publication date
CN119679944A (zh) 2025-03-25
SG11202006677XA (en) 2020-08-28
IL276180A (en) 2020-09-30
IL276180B2 (en) 2025-07-01
US20230107651A1 (en) 2023-04-06
IL276180B1 (en) 2025-03-01
EP3743728A1 (fr) 2020-12-02
AU2019211446A1 (en) 2020-09-10
AU2019211446B2 (en) 2025-07-03
KR102742415B1 (ko) 2024-12-12
US20210041459A1 (en) 2021-02-11
CN112567246A (zh) 2021-03-26
US11474113B2 (en) 2022-10-18
BR112020015082A2 (pt) 2021-01-05
JP2023118821A (ja) 2023-08-25
CL2020001936A1 (es) 2020-12-18
CN112567246B (zh) 2024-12-03
MX2020007852A (es) 2021-01-29
JP2021511389A (ja) 2021-05-06
JP7506606B2 (ja) 2024-06-26
WO2019147960A1 (fr) 2019-08-01
KR20200112906A (ko) 2020-10-05

Similar Documents

Publication Publication Date Title
EP3813808A4 (fr) Méthodes de traitement de la toxicomanie
EP3813647A4 (fr) Stimulation multimodale de traitement des tremblements
EP3645121A4 (fr) Méthodes de traitement de la maladie de huntington
EP3813806A4 (fr) Méthodes de traitement d'un dysfonctionnement mitochondrial
EP3644996A4 (fr) Procédés de traitement de la maladie de huntington
MA53329A (fr) Méthodes de traitement de l'épilepsie
MA45192A (fr) Traitement d'association
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
EP3946345A4 (fr) Méthodes de traitement de la douleur neuropathique
EP3285776A4 (fr) Méthodes de traitement d'infections bactériennes
EP3775263A4 (fr) Compositions et méthodes de traitement de l'acné
MA47504A (fr) Composés et méthodes de traitement de l'angiocholite biliaire primitive
EP3752161A4 (fr) Méthodes de traitement de la fibrose
EP3773632A4 (fr) Méthodes de traitement de glioblastomes exprimant l'egfrviii
EP3773633A4 (fr) Méthodes de traitement de glioblastomes
EP3454793A4 (fr) Bobines de traitement d'anévrisme
EP3745862A4 (fr) Méthodes de traitement de pathologies fibrotiques
EP3840752A4 (fr) Méthodes de traitement de la myélofibrose indépendantes du nombre de plaquettes
IL268905B (en) Phage therapy
MA46353A (fr) Méthodes de traitement de l'infertilité féminine
EP3599983A4 (fr) Endoscopes et méthodes de traitement
EP3630101A4 (fr) Méthodes de traitement de maladies
EP3634422A4 (fr) Méthodes de traitement de la leucodystrophie
EP3383857A4 (fr) Composés et méthodes de traitement d'infections bactériennes
EP3735209A4 (fr) Traitement de la progression de la myopie